This systematic review highlights the significant benefits of both beta-blockers and angiotensin-converting enzyme (ACE) inhibitors in managing chronic heart failure (CHF), particularly in reducing mortality, lowering hospital readmissions, and improving long-term outcomes. The gene discussed is ACE; the disease is congestive heart failure.